The influence of uremic serum and GSTM1 knockdown on redox homeostasis in HUVECs

Распространенные и зачастую сочетающиеся кардио- и цереброваскулярные заболевания (КЦВЗ), включающие артериальную гипертензию (АГ), ишемическую болезнь сердца (ИБС) и мозговой инсульт (МИ), представляют собой основную причину смертности во всем мире. Окислительный стресс имеет множество патологических эффектов на сосудистый гомеостаз и в настоящее время рассматривается как один из общих механизмов развития КЦВЗ. Целью исследования было изучение ассоциации однонуклеотидных полиморфизмов генов редокс-гомеостаза rs2070424 SOD1, rs4880 SOD2, rs769214 CAT, rs713041 GPX4, rs41303970 GCLM, rs17883901 GCLC, rs854560 PON1, rs7493 PON2, rs1695 GSTP1, rs2266782 FMO3 с развитием изолированных и сочетанных форм КЦВЗ. Материалом для исследования послужила выборка неродственных индивидов славянского происхождения, общей численностью 2702 человека. В исследование вошли 1815 пациентов с различными кардио- и цереброваскулярными заболеваниями и их сочетаниями: с изолированной АГ (иАГ), с изолированной ишемической болезнью сердца (иИБС), с сочетанием АГ и ИБС (АГ+ИБС), с мозговым инсультом (МИ) на фоне АГ (АГ+МИ); с коморбидной кардио- и цереброваскулярной патологией (АГ+ИБС+МИ). Из общей выборки здоровых лиц (N=887) были сформированы 5 контрольных групп, соответствующих по полу и возрасту каждой из групп нозологических форм заболеваний. Генотипирование SNP проводили методом ПЦР в режиме реального времени путем дискриминации аллелей с помощью TaqMan-зондов. Для анализа ассоциаций генотипов с развитием заболеваний пользовались лог-аддитивной регрессионной моделью. Все расчеты выполнены относительно минорного аллеля; введены поправки на пол и возраст. SNP rs1695 GSTP1 был связан исключительно с развитием иАГ (OR=1,19, 95%CI=1,01-1,39, р=0,034). SNP rs7493 PON2 был связан с развитием всех исследованных коморбидных кардио- и цереброваскулярных заболеваний: АГ+ИБС (adjOR=1,32, adj95%CI=1,07-1,63, adjp=0,01); АГ+МИ (adjOR=1,79, adj95%CI=1,45-2,21, adjp<0,0001); АГ+ИБС+МИ (adjOR=1,51, adj95%CI=1,09-2,09, adjp=0,01), а также с укорочением протромбинового времени (adjDifference=-0,35; adjp=0,01). SNP rs2266782 FMO3 был связан с фенотипом АГ+МИ (adjOR=1,24, adj95%CI=1,02-1,51, adjp=0,03), а также снижал возраст манифестации МИ (adjDifference=-2,31; adjp=0,03). Таким образом, установлено, что однонуклеотидные полиморфизмы генов редокс-гомеостаза могут представлять важную генетическую компоненту формирования дифференцированности кардио- и цереброваскулярных фенотипов. Common and often comorbid cardio- and cerebrovascular diseases (CCVD), including arterial hypertension (AH), coronary heart disease (CHD), and cerebral stroke (CS), are the leading cause of death worldwide. Oxidative stress has many pathological effects on vascular homeostasis and is currently regarded as one of the common mechanisms for the development of CCVD. The aim of our study was to investigate the association of single nucleotide polymorphisms of the redox-homeostasis genes rs2070424 SOD1, rs4880 SOD2, rs769214 CAT, rs713041 GPX4, rs41303970 GCLM, rs17883901 GCLC, rs854560 PON1, rs7493 PON2, rs1695 GSTP1, rs2266782 FMO3 with the development of isolated and comorbid CCVD. A total 2702 individuals of Slavic origin were included for this study. The patients group included 1815 subjects with various CCVD and their combinations: isolated AH (IAH); isolated IHD (IIHD), combination of AH and IHD (AH+IHD); combination of AH and CS (AH+CS); comorbid cardio- and cerebrovascular pathology (AH+IHD+CS). From the total sample of healthy individuals (N=887), 5 sex- and age-matched control groups were formed. Genotyping was performed using TaqMan-based PCR. To analyze the associations of genotypes with the risk of diseases, a log-additive regression model was used. All calculations were performed relative to the minor allele; corrections for gender and age have been introduced. SNP rs1695 GSTP1 was associated with IAH exclusively (OR=1.19, 95%CI=1.01-1.39, P=0.034). SNP rs7493 PON2 was associated with the development of all studied comorbid CCVD: AH+IHD (adjOR=1.32, adj95%CI=1.07-1.63, adjP=0.01); AH+CS (adjOR=1.79, adj95%CI=1.45-2.21, adjP<0.0001); AH+IHD+CS (adjOR=1.51, adj95%CI=1.09-2.09, adjP=0.01), as well as shortening of prothrombin time (adjDifference=-0.35; adjP=0.01). SNP rs2266782 FMO3 was associated with the development of AH+CS (adjOR=1.24, adj95%CI=1.02-1.51, adjP=0.03), as well as decreased age of manifestation of CS (adjDifference=-2.31; adjP=0.03). Thus, it was found that genes involved in regulation of redox-homeostasis, can represent an important genetic component in the formation of differentiation of cardio- and cerebrovascular phenotypes.

Download Full-text

Identification and Characterization of Novel Antioxidant Peptides Involved in Redox Homeostasis of Frog, Limnonectes fragilis

Protein and Peptide Letters ◽

10.2174/0929866522666150630104815 ◽

2015 ◽

Vol 22 (9) ◽

pp. 776-784 ◽

Cited By ~ 6

Author(s):

Haining Yu ◽

Xue Qiao ◽

Jiuxiang Gao ◽

Chen Wang ◽

Shasha Cai ◽

...

Keyword(s):

Redox Homeostasis ◽

Antioxidant Peptides ◽

Identification And Characterization

Download Full-text

Involvement of Heme Oxygenase-1 in Neuropsychiatric and Neurodegenerative Diseases

Current Pharmaceutical Design ◽

10.2174/1381612824666180717160623 ◽

2018 ◽

Vol 24 (20) ◽

pp. 2283-2302 ◽

Cited By ~ 9

Author(s):

Vivian B. Neis ◽

Priscila B. Rosa ◽

Morgana Moretti ◽

Ana Lucia S. Rodrigues

Keyword(s):

Neurodegenerative Diseases ◽

Heme Oxygenase ◽

Therapeutic Potential ◽

Redox Homeostasis ◽

Antioxidant Defenses ◽

Heme Oxygenase 1 ◽

Physiological Conditions ◽

And Oxidative Stress ◽

Defensive Mechanism

Heme oxygenase (HO) family catalyzes the conversion of heme into free iron, carbon monoxide and biliverdin. It possesses two well-characterized isoforms: HO-1 and HO-2. Under brain physiological conditions, the expression of HO-2 is constitutive, abundant and ubiquitous, whereas HO-1 mRNA and protein are restricted to small populations of neurons and neuroglia. HO-1 is an inducible enzyme that has been shown to participate as an essential defensive mechanism for neurons exposed to oxidant challenges, being related to antioxidant defenses in certain neuropathological conditions. Considering that neurodegenerative diseases (Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Multiple Sclerosis (MS)) and neuropsychiatric disorders (depression, anxiety, Bipolar Disorder (BD) and schizophrenia) are associated with increased inflammatory markers, impaired redox homeostasis and oxidative stress, conditions that may be associated with alterations in HO-levels/activity, the purpose of this review is to present evidence on the possible role of HO-1 in these Central Nervous System (CNS) diseases. In addition, the possible therapeutic potential of targeting brain HO-1 is explored in this review.

Download Full-text

An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmaniasis (VL)

Current Drug Targets ◽

10.2174/1389450121666200422083735 ◽

2020 ◽

Vol 21 (11) ◽

pp. 1105-1129

Author(s):

Rani Mansuri ◽

Jagbir Singh ◽

Anupama Diwan

Keyword(s):

Drug Targets ◽

Redox Homeostasis ◽

World Health ◽

Metabolism Pathway ◽

Thiol Metabolism ◽

Development Of Resistance ◽

Current Perspective ◽

Fatal Form ◽

Novel Target ◽

Health Organization

Leishmaniasis is one of the six entities on the list of most important diseases of the World Health Organization/Tropical Disease Research (WHO/TDR). After Malaria, it is one of the most prevalent and lethal parasitic diseases. VL is the fatal form of this disease, especially if left untreated. The drugs that are currently available for the treatment of VL are expensive, toxic, or no longer effective, especially in endemic regions. Currently, no vaccine has been developed to immunize humans against VL. The major problems with the current drugs are the development of resistance and their adverse effects. Therefore, there is a strong urge to research and design drugs that have better efficacies and low toxicities as compared to current chemotherapeutic drugs. Leishmania has various enzymes involved in its metabolic pathways, which are unique to either the same genus or trypanosomatids, making them a very suitable, attractive and novel target sites for drug development. One of the significant pathways unique to trypanosomatids is the thiol metabolism pathway, which is involved in the maintenance of redox homeostasis as well as protection of the parasite in the macrophage from oxidative stress-induced damage. In this review the several pathways, their essential enzymes as well as the proposed changes in the parasites due to drug resistance have been discussed to help to understand the most suitable drug target. The thiol metabolism pathway is discussed in detail, providing evidence of this pathway being the most favorable choice for drug targeting in VL.

Download Full-text

Targeting PPARalpha in Alzheimer's Disease

Current Alzheimer Research ◽

10.2174/1567205014666170505094549 ◽

2018 ◽

Vol 15 (4) ◽

pp. 345-354 ◽

Cited By ~ 13

Author(s):

Barbara D'Orio ◽

Anna Fracassi ◽

Maria Paola Cerù ◽

Sandra Moreno

Keyword(s):

Oxidative Stress ◽

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Molecular Mechanisms ◽

Redox Homeostasis ◽

Antioxidant Response ◽

Peroxisome Proliferator ◽

Prevailing Paradigm

Background: The molecular mechanisms underlying Alzheimer's disease (AD) are yet to be fully elucidated. The so-called “amyloid cascade hypothesis” has long been the prevailing paradigm for causation of disease, and is today being revisited in relation to other pathogenic pathways, such as oxidative stress, neuroinflammation and energy dysmetabolism. The peroxisome proliferator-activated receptors (PPARs) are expressed in the central nervous system (CNS) and regulate many physiological processes, such as energy metabolism, neurotransmission, redox homeostasis, autophagy and cell cycle. Among the three isotypes (α, β/δ, γ), PPARγ role is the most extensively studied, while information on α and β/δ are still scanty. However, recent in vitro and in vivo evidence point to PPARα as a promising therapeutic target in AD. Conclusion: This review provides an update on this topic, focussing on the effects of natural or synthetic agonists in modulating pathogenetic mechanisms at AD onset and during its progression. Ligandactivated PPARα inihibits amyloidogenic pathway, Tau hyperphosphorylation and neuroinflammation. Concomitantly, the receptor elicits an enzymatic antioxidant response to oxidative stress, ameliorates glucose and lipid dysmetabolism, and stimulates autophagy.

Download Full-text